First New ALS Treatment in Decades Approved by FDA

Radicava (edaravone) has been cleared as a therapeutic option for the disease.

It has been more than 20 years since a treatment for ALS has been approved by US regulators, but that changed on May 8 when the FDA announced its approval of Mitsubishi Tanabe Pharma Corp's Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), known commonly as Lou Gehrig’s disease in the US.

After learning that Japanese regulators approved the use of edaravone to treat ALS in Japan, the agency said it quickly reached out to Mitsubishi Tanabe to request they file a marketing application in the US. Eric Bastings, Deputy Director of the FDA’s Center for Drug Evaluation and Research remarked, “this is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

The Centers for Disease Control and Prevention find approximately 12-15,000 people suffer from the disease in the US. According to the FDA, the efficacy of edaravone was demonstrated in a clinical trial involving 137 people randomized to receive the drug or a placebo. By Week 24, patients receiving edaravone exhibited less decline than those receiving the placebo. 

 

Guy Tiene

Guy supports the success of life science organizations by identifying synergies across research, content, marketing and communications resources to drive value for clients. With over 30 years of education and marketing experience and 18 years in the life sciences alone, Guy leads our editorial standards for client content, Pharma’s Almanac and Nice Insight research-based industry content as well as external communications for clients. Having served as head of global marketing and communications for a CMO, he also brings critical insight and guidance to all communications. Guy holds a Masters degree from Columbia University.